Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines

BACKGROUND: Trastuzumab is a humanized monoclonal antibody (mAb) currently used for the treatment of breast cancer (BC) patients with HER-2 overexpressing tumor subtype. Previous data reported the involvement of FcγRIIIA/IIA gene polymorphisms and/or antibody-dependent cellular cytotoxicity (ADCC) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Boero, Silvia, Morabito, Anna, Banelli, Barbara, Cardinali, Barbara, Dozin, Beatrice, Lunardi, Gianluigi, Piccioli, Patrizia, Lastraioli, Sonia, Carosio, Roberta, Salvi, Sandra, Levaggi, Alessia, Poggio, Francesca, D’Alonzo, Alessia, Romani, Massimo, Del Mastro, Lucia, Poggi, Alessandro, Pistillo, Maria Pia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598965/
https://www.ncbi.nlm.nih.gov/pubmed/26450443
http://dx.doi.org/10.1186/s12967-015-0680-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598965/
https://www.ncbi.nlm.nih.gov/pubmed/26450443
http://dx.doi.org/10.1186/s12967-015-0680-0

Ejemplares similares